Display options
Cite
Mazurkiewicz E, Makowiecka A, Mrówczyńska E, et al. Gelsolin Contributes to the Motility of A375 Melanoma Cells and This Activity Is Mediated by the Fibrous Extracellular Matrix Protein Profile. Cells. 2021;10(8)doi: 10.3390/cells10081848.
Mazurkiewicz, E., Makowiecka, A., Mrówczyńska, E., Kopernyk, I., Nowak, D., & Mazur, A. J. (2021). Gelsolin Contributes to the Motility of A375 Melanoma Cells and This Activity Is Mediated by the Fibrous Extracellular Matrix Protein Profile. Cells, 10(8), . https://doi.org/10.3390/cells10081848
Mazurkiewicz, Ewa, et al. "Gelsolin Contributes to the Motility of A375 Melanoma Cells and This Activity Is Mediated by the Fibrous Extracellular Matrix Protein Profile." Cells vol. 10,8 (2021). doi: https://doi.org/10.3390/cells10081848
Mazurkiewicz E, Makowiecka A, Mrówczyńska E, Kopernyk I, Nowak D, Mazur AJ. Gelsolin Contributes to the Motility of A375 Melanoma Cells and This Activity Is Mediated by the Fibrous Extracellular Matrix Protein Profile. Cells. 2021 Jul 21;10(8). doi: 10.3390/cells10081848. PMID: 34440617; PMCID: PMC8394273.
Copy Download .nbib Format: NLM
Share it on

Cells. 2021 Jul 21;10(8). doi: 10.3390/cells10081848.

Gelsolin Contributes to the Motility of A375 Melanoma Cells and This Activity Is Mediated by the Fibrous Extracellular Matrix Protein Profile.

Cells

Ewa Mazurkiewicz, Aleksandra Makowiecka, Ewa Mrówczyńska, Iryna Kopernyk, Dorota Nowak, Antonina Joanna Mazur

Affiliations

  1. Department of Cell Pathology, Faculty of Biotechnology, University of Wroclaw, 50-383 Wroclaw, Poland.

PMID: 34440617 PMCID: PMC8394273 DOI: 10.3390/cells10081848

Abstract

Skin melanocytes reside on the basement membrane (BM), which is mainly composed of laminin, collagen type IV, and proteoglycans. For melanoma cells, in order to invade into the skin, melanocytes must cross the BM. It has been reported that changes in the composition of the BM accompany melanocytes tumorigenesis. Previously, we reported high gelsolin (GSN)-an actin-binding protein-levels in melanoma cell lines and GSN's importance for migration of A375 cells. Here we investigate whether melanoma cells migrate differently depending on the type of fibrous extracellular matrix protein. We obtained A375 melanoma cells deprived of GSN synthesis and tested their migratory properties on laminin, collagens type I and IV, fibronectin, and Matrigel, which resembles the skin's BM. We applied confocal and structured illuminated microscopy (SIM), gelatin degradation, and diverse motility assays to assess GSN's influence on parameters associated with cells' ability to protrude. We show that GSN is important for melanoma cell migration, predominantly on laminin, which is one of the main components of the skin's BM.

Keywords: CRISPR/Cas9(D10A) technique; Matrigel; SIM; actin cytoskeleton; collagen; extracellular matrix (ECM); fibronectin; gelsolin (GSN); invasion; laminin; melanoma; motility

References

  1. J Cell Sci. 2021 Apr 15;134(8): - PubMed
  2. Cells. 2021 Apr 09;10(4): - PubMed
  3. Int J Mol Sci. 2020 Apr 15;21(8): - PubMed
  4. Front Oncol. 2019 Dec 06;9:1370 - PubMed
  5. Science. 1999 Aug 13;285(5430):1028-32 - PubMed
  6. J Cell Biol. 2017 Oct 2;216(10):3387-3403 - PubMed
  7. J Cell Biol. 1997 Sep 22;138(6):1279-87 - PubMed
  8. Cancer Cell Int. 2019 Mar 29;19:77 - PubMed
  9. Curr Top Dev Biol. 2018;130:1-37 - PubMed
  10. Cytoskeleton (Hoboken). 2013 Jul;70(7):385-93 - PubMed
  11. Nature. 1979 Oct 18;281(5732):583-6 - PubMed
  12. Cancers (Basel). 2020 Oct 06;12(10): - PubMed
  13. Exp Cell Res. 2011 May 1;317(8):1119-33 - PubMed
  14. Curr Opin Cell Biol. 2019 Feb;56:53-63 - PubMed
  15. Cancer Cell. 2019 Mar 18;35(3):347-367 - PubMed
  16. Physiol Rev. 2014 Jan;94(1):235-63 - PubMed
  17. Cells. 2021 Mar 31;10(4): - PubMed
  18. J Exp Clin Cancer Res. 2018 Oct 5;37(1):245 - PubMed
  19. Arch Dermatol Res. 1979 Aug;266(1):33-41 - PubMed
  20. J Biol Chem. 2011 Apr 15;286(15):13438-47 - PubMed
  21. Cancer Res. 2004 May 15;64(10):3572-9 - PubMed
  22. J Invest Dermatol. 1989 May;92(5):663-8 - PubMed
  23. Hematol Oncol Clin North Am. 2014 Jun;28(3):507-21 - PubMed
  24. Melanoma Res. 2002 Dec;12(6):523-8 - PubMed
  25. Int J Cancer. 2001 Sep;93(6):773-80 - PubMed
  26. Med Res Rev. 2012 Sep;32(5):999-1025 - PubMed
  27. Biochemistry. 1998 Apr 14;37(15):5279-87 - PubMed
  28. Mol Cancer. 2010 Oct 22;9:280 - PubMed
  29. Expert Rev Mol Med. 2019 Jan 30;20:e7 - PubMed
  30. Int J Dev Biol. 2010;54(5):887-96 - PubMed
  31. J Pathol. 2019 Apr;247(5):539-551 - PubMed
  32. Int J Mol Sci. 2018 Aug 25;19(9): - PubMed
  33. J Cancer Res Clin Oncol. 2018 Dec;144(12):2283-2302 - PubMed
  34. Eur J Histochem. 2016 Dec 09;60(4):2728 - PubMed
  35. Life Sci. 2012 Jun 6;90(21-22):851-61 - PubMed
  36. Sci Rep. 2019 Feb 20;9(1):2425 - PubMed
  37. Hum Pathol. 1984 Dec;15(12):1147-65 - PubMed
  38. Int J Mol Sci. 2021 Jan 07;22(2): - PubMed
  39. Cell. 1995 Apr 7;81(1):53-62 - PubMed
  40. Cancer Res. 1989 Sep 1;49(17):4796-802 - PubMed
  41. Int J Cancer. 2004 Oct 10;111(6):873-80 - PubMed
  42. Oncogene. 2018 Jun;37(23):3166-3182 - PubMed
  43. Methods Mol Biol. 2021;2265:47-63 - PubMed
  44. Semin Cancer Biol. 2005 Oct;15(5):378-86 - PubMed
  45. Cancer Res. 1997 May 15;57(10):2061-70 - PubMed
  46. Sci Rep. 2015 Jan 20;5:7901 - PubMed
  47. EMBO J. 1993 Dec;12(12):4795-802 - PubMed
  48. J Cell Biol. 2005 Jan 31;168(3):441-52 - PubMed
  49. Endocr Relat Cancer. 2005 Jun;12(2):393-406 - PubMed
  50. Int J Cell Biol. 2010;2010:507821 - PubMed
  51. Eur J Cell Biol. 2012 Nov-Dec;91(11-12):896-901 - PubMed
  52. Biomed Res Int. 2013;2013:179784 - PubMed
  53. J Cutan Pathol. 2000 Feb;27(2):67-75 - PubMed
  54. J Natl Cancer Inst. 1984 Apr;72(4):889-99 - PubMed
  55. Biomaterials. 2008 May;29(15):2293-305 - PubMed
  56. Cell. 2006 Jun 30;125(7):1361-74 - PubMed
  57. J Biol Chem. 2003 Apr 18;278(16):14321-30 - PubMed
  58. J Tissue Eng. 2014 Dec 20;5:2041731414557112 - PubMed
  59. Sci Rep. 2021 Feb 8;11(1):3329 - PubMed
  60. Biochemistry. 1986 Jan 28;25(2):312-8 - PubMed
  61. Int J Cancer. 2008 Mar 1;122(5):1019-29 - PubMed
  62. J Cutan Pathol. 1999 May;26(5):222-6 - PubMed
  63. Cytoskeleton (Hoboken). 2013 Jul;70(7):360-84 - PubMed
  64. Int J Mol Sci. 2020 Nov 07;21(21): - PubMed
  65. J Proteome Res. 2009 Aug;8(8):3824-33 - PubMed
  66. Onco Targets Ther. 2019 May 01;12:3207-3221 - PubMed
  67. EMBO J. 2003 May 15;22(10):2318-23 - PubMed
  68. Eur J Cell Biol. 2016 Jan;95(1):26-41 - PubMed
  69. Biochem Biophys Res Commun. 2005 Aug 12;333(4):1269-75 - PubMed
  70. Cancer Cell. 2015 Apr 13;27(4):574-88 - PubMed
  71. Cell Adh Migr. 2014;8(3):273-9 - PubMed
  72. Curr Opin Cell Biol. 2015 Oct;36:23-31 - PubMed
  73. Proc Natl Acad Sci U S A. 2012 Sep 4;109(36):14434-9 - PubMed
  74. Crit Rev Oncol Hematol. 2004 Mar;49(3):221-33 - PubMed
  75. Cancers (Basel). 2020 Jul 15;12(7): - PubMed
  76. Oncogene. 2003 Jan 9;22(1):98-108 - PubMed
  77. Int J Clin Exp Med. 2015 Feb 15;8(2):1862-70 - PubMed
  78. Adv Drug Deliv Rev. 2016 Feb 1;97:28-40 - PubMed

Substances

MeSH terms

Publication Types

Grant support